Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Biofilms are microbial communities, embedded in a polymeric matrix, growing attached to a surface. Nearly all device-associated infections involve growth in the biofilm life style. Biofilm communities have characteristic architecture and distinct phenotypic properties. The most clinically important phenotype involves extraordinary resistance to antimicrobial therapy, making biofilm infections very difficulty to cure without device removal. The current studies examine drug resistance in Candida albicans biofilms. Similar to previous reports, we observed marked fluconazole and amphotericin B resistance in a C. albicans biofilm both in vitro and in vivo. We identified biofilm-associated cell wall architectural changes and increased β-1,3 glucan content in C. albicans cell walls from a biofilm compared to planktonic organisms. Elevated β-1,3 glucan levels were also found in the surrounding biofilm milieu and as part of the matrix both from in vitro and in vivo biofilm models. We thus investigated the possible contribution of β-glucans to antimicrobial resistance in Candida albicans biofilms. Initial studies examined the ability of cell wall and cell supernatant from biofilm and planktonic C. albicans to bind fluconazole. The cell walls from both environmental conditions bound fluconazole; however, four- to fivefold more compound was bound to the biofilm cell walls. Culture supernatant from the biofilm, but not planktonic cells, bound a measurable amount of this antifungal agent. We next investigated the effect of enzymatic modification of β-1,3 glucans on biofilm cell viability and the susceptibility of biofilm cells to fluconazole and amphotericin B. We observed a dose-dependent killing of in vitro biofilm cells in the presence of three different β-glucanase preparations. These same concentrations had no impact on planktonic cell viability. β-1,3 Glucanase markedly enhanced the activity of both fluconazole and amphotericin B. These observations were corroborated with an in vivo biofilm model. Exogenous biofilm matrix and commercial β-1,3 glucan reduced the activity of fluconazole against planktonic C. albicans in vitro. In sum, the current investigation identified glucan changes associated with C. albicans biofilm cells, demonstrated preferential binding of these biofilm cell components to antifungals, and showed a positive impact of the modification of biofilm β-1,3 glucans on drug susceptibility. These results provide indirect evidence suggesting a role for glucans in biofilm resistance and present a strong rationale for further molecular dissection of this resistance mechanism to identify new drug targets to treat biofilm infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, although β-1,3-glucans contribute to drug resistance and are the major cell wall polysaccharide (130), we now know that they constitute only a small fraction of the total polysaccharides present, implying that the matrix is not constructed simply of released cell wall constituents.”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One known constituent of the biofilm matrix that contributes to its drug-resistance properties is the polysaccharide β-1,3-glucan (130).”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Few studies have shown that fluconazole-resistant (FR) C. albicans may also exhibit higher levels of β-glucans compared to susceptible strains (12, 16).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher levels of β-glucans absorb fluconazole and inhibit its penetration to the site of action (12).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“β-glucans can act as a physical barrier, reducing the accessibility of fluconazole to its target sites in the cell membrane and limiting its effectiveness (12).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colorimetric Method for Determination of Sugars and Related Substances
DuBois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., & Smith, F. (1956) · Analytical Chemistry · doi:10.1021/ac60111a017 · Cited by 52,269 · cited 1×
“Carbohydrate concentrations of each fraction were measured as hexoses by the phenol-sulfuric method as previously described (18, 22 , 40).”
MethodBacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167 · cited 1×
“Biofilms are structured microbial communities in which organisms irreversibly attach to a surface and become embedded in a matrix of extracellular polymeric substances produced by these cells (6, 15, 17 , 20, 21, 24, 41, 46, 50).”
BackgroundBiofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 1×
“Biofilms are structured microbial communities in which organisms irreversibly attach to a surface and become embedded in a matrix of extracellular polymeric substances produced by these cells (6, 15, 17, 20 , 21, 24, 41, 46, 50).”
BackgroundMechanisms of biofilm resistance to antimicrobial agents
Mah, T.-F. C., & O'Toole, G. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01913-2 · Cited by 3,921 · cited 2×
“Previous studies in a bacterial biofilm model demonstrated sequestration of antimicrobial compounds by a cell wall component, specifically, the -1,3 glucan component of biofilm cells (33, 34 ).”
BackgroundMethods in yeast genetics : a Cold Spring Harbor Laboratory course manual
Amberg, D. C., Burke, D. J., & Strathern, J. N. (2005) · Cited by 1,803
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578 · cited 1×
“25 g/ml for fluconazole and amphotericin B, respectively [2, 6, 7, 9, 11, 15, 25, 30, 31, 47].”
BackgroundGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 3×
“C. albicans is a major human pathogen which can grow as a biofilm and inhabit the surface of many medical devices (28, 44 ).”
BackgroundInfluentialClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“A number of molecular mechanisms have been implicated in nonbiofilm antifungal resistance in C. albicans ( 54 ).”
BackgroundA genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance
Mah, T.-F., Pitts, B., Pellock, B., Walker, G. C., Stewart, P. S., & O'Toole, G. A. (2003) · Nature · doi:10.1038/nature02122 · Cited by 1,190
Candida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150 · cited 2×
“Biofilms are the most common form of microbial growth in nature, and the National Institutes of Health estimate that biofilms cause the majority of infections in humans ( 21 , 28, 45, 46).”
Background
Research works printed but not linked: 1
- 10.1002/(sici)1097-0061(19960615)12:7<683::aid-yea959>3.0.co;2-8 · DOI
Cited by
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423
Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., & Mendes Giannini, M. J. S. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.045054-0 · Cited by 1,184
“The primary component of biofilm matrix is b-glucan (Finkel & Mitchell, 2011; Nett et al., 2007).”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Candida albicans biofilms: development, regulation, and molecular mechanisms
Gulati, M., & Nobile, C. J. (2016) · Microbes and Infection · doi:10.1016/j.micinf.2016.01.002 · Cited by 738
Candida Biofilms: Threats, Challenges, and Promising Strategies
Cavalheiro, M., & Teixeira, M. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00028 · Cited by 690
“albicans susceptibility to fluconazole and amphotericin B (99).”
BackgroundDevelopment and regulation of single- and multi-species Candida albicans biofilms
Lohse, M. B., Gulati, M., Johnson, A. D., & Nobile, C. J. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.107 · Cited by 643
Genetic control of Candida albicans biofilm development
Finkel, J. S., & Mitchell, A. P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2475 · Cited by 612
Ramage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
Falsetta, M. L., Klein, M. I., Colonne, P. M., Scott-Anne, K., Gregoire, S., Pai, C.-H., Gonzalez-Begne, M., Watson, G., Krysan, D. J., Bowen, W. H., et al. (2014) · Infection and Immunity · doi:10.1128/iai.00087-14 · Cited by 561
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms
Van Acker, H., Van Dijck, P., & Coenye, T. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.02.001 · Cited by 520
Oral Candidiasis: A Disease of Opportunity
Vila, T., Sultan, A. S., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2020) · Journal of Fungi · doi:10.3390/jof6010015 · Cited by 537
Pathogenesis of Candida albicans biofilm
Tsui, C., Kong, E. F., & Jabra-Rizk, M. A. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw018 · Cited by 481
“In C. albicans, the biofilm matrix is largely composed of polysaccharides such as β-1,3-glucan, β-1,6-glucan, and mannans and to a lesser extent, proteins (Al-Fattani and Douglas 2006; Nett et al. 2007; Nett, Sanchez and Andes 2011; Zarnowski et al. 2014).”
BackgroundOur Current Understanding of Fungal Biofilms
Ramage, G., Mowat, E., Jones, B., Williams, C., & Lopez-Ribot, J. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903241436 · Cited by 483
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
Self-citationBiofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
“The matrix acts as a physical barrier to drug penetration and as a stabilizer of the overall biofilm architecture (Nett et al. 2007; Nobile and Johnson 2015).”
BackgroundBiofilm Matrix Regulation by Candida albicans Zap1
Nobile, C. J., Nett, J. E., Hernday, A. D., Homann, O. R., Deneault, J.-S., Nantel, A., Andes, D. R., Johnson, A. D., & Mitchell, A. P. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000133 · Cited by 337
“The distal 2 cm of the catheter was cut from the entire catheter length, and biofilms were imaged by SEM at 506 and 1,0006magnification, as described previously [9].”
BackgroundMethodSelf-citationCandida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323
“Importantly, these mature biofilms are encased within a self-produced protective extracellular matrix (ECM) which also imparts most of its resistance properties [34, 35].”
BackgroundCandida Species Biofilms’ Antifungal Resistance
Silva, S., Rodrigues, C., Araújo, D., Rodrigues, M., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010008 · Cited by 302
“Interestingly, transcriptional analysis of a rat venous catheter biofilm also found increased transcription of ERG25, but not ERG11 [134].”
BackgroundNovel Entries in a Fungal Biofilm Matrix Encyclopedia
Zarnowski, R., Westler, W. M., Lacmbouh, G. A., Marita, J. M., Bothe, J. R., Bernhardt, J., Lounes-Hadj Sahraoui, A., Fontaine, J., Sanchez, H., Hatfield, R. D., et al. (2014) · mBio · doi:10.1128/mbio.01333-14 · Cited by 315
Self-citationThe evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Kong, E. F., Tsui, C., Kucharíková, S., Andes, D., Van Dijck, P., & Jabra-Rizk, M. A. (2016) · mBio · doi:10.1128/mbio.01365-16 · Cited by 294
Self-citationCandida albicans forms biofilms on the vaginal mucosa
Harriott, M. M., Lilly, E. A., Rodriguez, T. E., Fidel, P. L., & Noverr, M. C. (2010) · Microbiology · doi:10.1099/mic.0.039354-0 · Cited by 301
“ConA is a lectin that binds to C. albicans polysaccharides secreted as part of the matrix. b-Glucan is a cell wall polysaccharide that has been detected in Candida ECM by a Limulus amoebocyte lysate clotting enzyme based assay (Nett et al., 2007a, b).”
MethodHsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
Self-citationA Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance
Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., Hamaker, J., Mitchell, A. P., & Andes, D. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002848 · Cited by 291
“albicans matrix is b-1,3 glucan [16,31].”
BackgroundMethodResultSelf-citationSanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
“Biofilms can also sequester antifungal agents (azoles, amphotericin B) in the polymers of the matrix and thus neutralize their inhibitory effects (Nett et al., 2007).”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Candida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
“…including alterations in transcriptional network activity (Yeater et al. 2007; Nobile et al. 2012; Fox et al. 2015), altered cell wall architecture (Nett et al. 2007), differences in ergosterol content of biofilm cell plasma membranes (Mukherjee et al. 2003) and, most notably, differences in…”
BackgroundRoscetto, E., Contursi, P., Vollaro, A., Fusco, S., Notomista, E., & Catania, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35530-0 · Cited by 272
Recent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
“A new light was shed on the matter when Nett et al. (2007b) discovered that cell walls of biofilm-associated cells were up to two times thicker and contained more carbohydrates and b-1,3-glucans than stationary or logphase planktonic cells.”
InfluentialIn vivo biofilm composition of Aspergillus fumigatus
Loussert, C., Schmitt, C., Prevost, M.-C., Balloy, V., Fadel, E., Philippe, B., Kauffmann-Lacroix, C., Latgé, J. P., & Beauvais, A. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01409.x · Cited by 269
“In contrast to A. fumigatus, the ECM of Candidia albicans is rich in b-1,3 glucan, whereas an a-1,2-1,6 mannan is found in Saccharomyces cerevisiae during flocculation (Nett et al., 2007; Beauvais et al., 2009).”
ResultFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Fungal Biofilms, Drug Resistance, and Recurrent Infection
Desai, J. V., Mitchell, A. P., & Andes, D. R. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019729 · Cited by 252
“The role for matrix b-1,3 glucan in biofilm drug resistance during clinical infection was supported by the synergistic action of glucanase and fluconazole on rat venous catheters infected with C. albicans (Nett et al. 2007).”
BackgroundMethodSelf-citationHöfs, S., Mogavero, S., & Hube, B. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5514-0 · Cited by 238
“…including a reduced growth rate of the cells, upregulation of drug efflux pumps, the presence of persister cells and an impermeable extracellular matrix (Baillie and Douglas, 1998; Ramage et al., 2002; Sanglard, 2002; Al-Fattani and Douglas, 2006; LaFleur et al., 2006; Nett et al., 2007, 2009).”
BackgroundGenetic Basis of Candida Biofilm Resistance Due to Drug‐Sequestering Matrix Glucan
Nett, J. E., Sanchez, H., Cain, M. T., & Andes, D. R. (2010) · The Journal of Infectious Diseases · doi:10.1086/651200 · Cited by 250
“[2,10].”
BackgroundMethodSelf-citationSynergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228
“A recent report also demonstrated that cell wall -1,3 glucan levels contribute to biofilm resistance to fluconazole (22).”
BackgroundMethodSelf-citationPortrait of Candida albicans Adherence Regulators
Finkel, J. S., Xu, W., Huang, D., Hill, E. M., Desai, J. V., Woolford, C. A., Nett, J. E., Taff, H., Norice, C. T., Andes, D. R., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002525 · Cited by 228
“albicans infection catheters are removed from the rat and the distal 2 cm of catheter material is removed and assayed for biofilm growth via imaging using scanning electron microscopy (SEM) [48].”
MethodSelf-citationFungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
“Comparisons between biofilm (AMB-resistant) and planktonic (AMB-susceptible) C. albicans cells revealed that the cell wall from the biofilm-grown isolates are thicker and have more β-1,3-glucans (Nett et al., 2007).”
BackgroundBiofilm-Associated Infections: Antibiotic Resistance and Novel Therapeutic Strategies
Sun, F., Qu, F., Ling, Y., Mao, P., Xia, P., Chen, H., & Zhou, D. (2013) · Future Microbiology · doi:10.2217/fmb.13.58 · Cited by 212
Global Gene Deletion Analysis Exploring Yeast Filamentous Growth
Ryan, O., Shapiro, R. S., Kurat, C. F., Mayhew, D., Baryshnikova, A., Chin, B., Lin, Z.-Y., Cox, M. J., Vizeacoumar, F., Cheung, D., et al. (2012) · Science · doi:10.1126/science.1224339 · Cited by 213
Kean, R., Rajendran, R., Haggarty, J., Townsend, E. M., Short, B., Burgess, K. E., Lang, S., Millington, O., Mackay, W. G., Williams, C., et al. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00258 · Cited by 195
“The effective disruption of C. albicans matrix components to enhance antimicrobial efficacy has also been demonstrated within in vitro mono- and dual-species biofilms (Nett et al., 2007; Rajendran et al., 2014; De Brucker et al., 2015; Kong et al., 2016).”
BackgroundTorosantucci, A., Chiani, P., Bromuro, C., De Bernardis, F., Palma, A. S., Liu, Y., Mignogna, G., Maras, B., Colone, M., Stringaro, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005392 · Cited by 204
Nett, J. E., Crawford, K., Marchillo, K., & Andes, D. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00227-10 · Cited by 207
Self-citationMolecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
Polke, M., Hube, B., & Jacobsen, I. D. (2015) · Advances in Applied Microbiology · doi:10.1016/bs.aambs.2014.12.002 · Cited by 184
Mucosal biofilms of Candida albicans
Ganguly, S., & Mitchell, A. P. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.06.001 · Cited by 200
Promising Therapeutic Strategies Against Microbial Biofilm Challenges
Zhang, K., Li, X., Yu, C., & Wang, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00359 · Cited by 190
Candida albicans, plasticity and pathogenesis
Poulain, D. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.813904 · Cited by 173
“Glucanase treatment increased the susceptibility of biofilms to azoles and polyenes whereas, conversely, the addition of glucans released from the biofilm matrix or laminarin, a b-1,3 glucan extracted from algae, increased the MIC of C. albicans strains in vitro (Nett et al., 2007).”
BackgroundVediyappan, G., Rossignol, T., & d'Enfert, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01638-09 · Cited by 183
Community participation in biofilm matrix assembly and function
Mitchell, K. F., Zarnowski, R., Sanchez, H., Edward, J. A., Reinicke, E. L., Nett, J. E., Mitchell, A. P., & Andes, D. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421437112 · Cited by 183
Self-citationTsai, P.-W., Yang, C.-Y., Chang, H.-T., & Lan, C.-Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017755 · Cited by 175
Microfluidic Approaches to Bacterial Biofilm Formation
Kim, J., Park, H.-D., & Chung, S. (2012) · Molecules · doi:10.3390/molecules17089818 · Cited by 170
“The biofilm matrix provides microorganisms with a protective shield that contributes significantly to several clinical challenges, including symptomatic inflammation, antibiotic resistance, recurrence, and the spread of infectious emboli [2–6].”
BackgroundMartins, M., Henriques, M., Lopez‐Ribot, J. L., & Oliveira, R. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02047.x · Cited by 174
“multifactorial and has been associated with factors such as cells physiological state, activation of drug efflux pumps [2], and a protective effect of the extracellular matrix (ECM) namely β-glucans that have been shown to bind fluconazole [3] and amphotericin B [4].”
BackgroundAn expanded regulatory network temporally controls C andida albicans biofilm formation
Fox, E. P., Bui, C. K., Nett, J. E., Hartooni, N., Mui, M. C., Andes, D. R., Nobile, C. J., & Johnson, A. D. (2015) · Molecular Microbiology · doi:10.1111/mmi.13002 · Cited by 173
“As the biofilm develops, a protein- and carbohydrate-rich extracellular matrix forms, which encases the biofilm and plays a key role in drug resistance (Hawser et al., 1998; Nett et al., 2007; 2010a,b; Zarnowski et al., 2014).”
BackgroundSelf-citationRajendran, R., Williams, C., Lappin, D. F., Millington, O., Martins, M., & Ramage, G. (2013) · Eukaryotic Cell · doi:10.1128/ec.00287-12 · Cited by 173
The Candida albicans Biofilm Matrix: Composition, Structure and Function
Pierce, C., Vila, T., Romo, J., Montelongo-Jauregui, D., Wall, G., Ramasubramanian, A., & Lopez-Ribot, J. (2017) · Journal of Fungi · doi:10.3390/jof3010014 · Cited by 159
Antifungal drug resistance of oral fungi
Niimi, M., Firth, N. A., & Cannon, R. D. (2010) · Odontology · doi:10.1007/s10266-009-0118-3 · Cited by 166
Nett, J. E., Sanchez, H., Cain, M. T., Ross, K. M., & Andes, D. R. (2011) · Eukaryotic Cell · doi:10.1128/ec.05126-11 · Cited by 168
Self-citationBiofilm formation in medically important Candida species
Malinovská, Z., Čonková, E., & Váczi, P. (2023) · Journal of Fungi · doi:10.3390/jof9100955 · Cited by 167
“The absence of β -1,3 glucan in the matrix increases the sensitivity of C. albicans to fluconazole and amphotericin B [41,70,81,100].”
BackgroundTime Course Global Gene Expression Analysis of an In Vivo Candida Biofilm
Nett, J. E., Lepak, A. J., Marchillo, K., & Andes, D. R. (2009) · The Journal of Infectious Diseases · doi:10.1086/599838 · Cited by 162
“periments as previously described [11, 13, 14].”
Self-citationContributions of the Biofilm Matrix to Candida Pathogenesis
Nett, J. E., & Andes, D. R. (2020) · Journal of Fungi · doi:10.3390/jof6010021 · Cited by 179
Self-citationDevelopment and Validation of an In Vivo Candida albicans Biofilm Denture Model
Nett, J. E., Marchillo, K., Spiegel, C. A., & Andes, D. R. (2010) · Infection and Immunity · doi:10.1128/iai.00480-10 · Cited by 161
Self-citationBiofilms and vulvovaginal candidiasis
Rodríguez‐Cerdeira, C., Carnero-Gregorio, M., Molares-Vila, A., López-Bárcenas, A., Fabbrocini, G., Bardhi, B., Sinani, A., Sánchez-Blanco, E., Arenas, R., & Hernández‐Castro, R. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.11.011 · Cited by 179
The Interface between Fungal Biofilms and Innate Immunity
Kernien, J. F., Snarr, B. D., Sheppard, D. C., & Nett, J. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01968 · Cited by 170
Self-citationMolecular and Cellular Mechanisms That Lead to Candida Biofilm Formation
ten Cate, J. M., Klis, F. M., Pereira‐Cenci, T., Crielaard, W., & de Groot, P. W. J. (2009) · Journal of Dental Research · doi:10.1177/0022034508329273 · Cited by 157
Nett, J. E., Cain, M. T., Crawford, K., & Andes, D. R. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02273-10 · Cited by 153
Self-citationCandida spp./Bacteria Mixed Biofilms
Rodrigues, M. E., Gomes, F., & Rodrigues, C. F. (2019) · Journal of Fungi · doi:10.3390/jof6010005 · Cited by 155
Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance
Kowalski, C. H., Morelli, K. A., Schultz, D., Nadell, C. D., & Cramer, R. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003700117 · Cited by 161
Bonhomme, J., Chauvel, M., Goyard, S., Roux, P., Rossignol, T., & d'Enfert, C. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07626.x · Cited by 144
“Soluble b-glucans are components of the ECM and have been shown to play a role in antifungal tolerance of the biofilms through their ability to trap azoles and polyenes en route to the biofilm cells (Nett et al., 2007; 2010a,b; Vediyappan et al., 2010).”
BackgroundKim, D., Liu, Y., Benhamou, R. I., Sánchez, H., Simón‐Soro, Á., Li, Y. H., Hwang, G., Fridman, M., Andes, D. R., & Koo, H. (2018) · The ISME Journal · doi:10.1038/s41396-018-0113-1 · Cited by 145
Self-citationMecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos
Espinel‐Ingroff, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70027-5 · Cited by 142
Portrait of Candida Species Biofilm Regulatory Network Genes
Araújo, D., Henriques, M., & Silva, S. M. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.09.004 · Cited by 154
Fan, F., Liu, Y., Liu, Y., Lv, R., Sun, W., Ding, W., Cai, Y., Li, W., Liu, X., & Qu, W. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106673 · Cited by 159
Dale, J. L., Cagnazzo, J., Phan, C. Q., Barnes, A. M. T., & Dunny, G. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00344-15 · Cited by 147
Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions
Mitchell, K. F., Zarnowski, R., & Andes, D. R. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005828 · Cited by 132
Self-citationBiofilm Exopolysaccharides of Pathogenic Fungi: Lessons from Bacteria
Sheppard, D. C., & Howell, P. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.720995 · Cited by 136
Candida albicans biofilms: building a heterogeneous, drug-tolerant environment
Bonhomme, J., & d’Enfert, C. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.007 · Cited by 120
Vanreppelen, G., Wuyts, J., Dijck, P. V., & Vandecruys, P. (2023) · Journal of Fungi · doi:10.3390/jof9020171 · Cited by 128
“The reduced efficacy of these antifungals on biofilms is attributed to their sequestration by the extracellular matrix containing β-glucan, which reduces the antifungal concentration able to reach the target cells, resulting in increased tolerance of cells within the biofilm [62,63].”
BackgroundMicrobial Biofilms in Pulmonary and Critical Care Diseases
Boisvert, A.-A., Cheng, M. P., Sheppard, D. C., & Nguyen, D. M. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201603-194fr · Cited by 122
Azole Drugs Are Imported By Facilitated Diffusion in Candida albicans and Other Pathogenic Fungi
Mansfield, B. E., Oltean, H. N., Oliver, B. G., Hoot, S. J., Leyde, S. E., Hedstrom, L., & White, T. C. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001126 · Cited by 111
Biofilm-Based Central Line-Associated Bloodstream Infections
Yousif, A., Jamal, M. A., & RAAD, I. I. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-11038-7_10 · Cited by 118
Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms
Mitchell, K. F., Taff, H. T., Cuevas, M. A., Reinicke, E. L., Sanchez, H., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02378-12 · Cited by 104
Self-citationKatragkou, A., Kruhlak, M. J., Simitsopoulou, M., Chatzimoschou, A., Ταπάρκου, Ά., Cotten, C. J., Paliogianni, F., Diza-Mataftsi, E., Tsantali, C., Walsh, T. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652783 · Cited by 117
“One of the principal characteristics of biofilms is their resistance to commonly used antifungal agents [9,10].”
BackgroundNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Uppuluri, P., Srinivasan, A., Ramasubramanian, A. K., & Lopez-Ribot, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01701-10 · Cited by 111
Brucker, K. D., Tan, Y., Vints, K., Cremer, K. D., Braem, A., Verstraeten, N., Michiels, J. J., Vleugels, J., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04650-14 · Cited by 107
Absence of Amphotericin B-Tolerant Persister Cells in Biofilms of Some Candida Species
Al-Dhaheri, R. S., & Douglas, L. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01473-07 · Cited by 99
“Cell density (20), membrane sterols (18), and cell wall glucans ( 19 ) could also play a role.”
BackgroundWhat We Do Not Know about Fungal Cell Adhesion Molecules
Lipke, P. N. (2018) · Journal of Fungi · doi:10.3390/jof4020059 · Cited by 109
“• How widespread are adhesive glycans and what are their roles [6,93]? • Structure and function of surface glues that stick fungi to hosts are open questions.”
BackgroundAnghel, I., Grumezescu, A. M., Holban, A. M., Ficai, A., Anghel, A. G., & Chifiriuc, M. C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918110 · Cited by 96
Candida albicans Biofilm Development and Its Genetic Control
Desai, J. V., & Mitchell, A. P. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0005-2014 · Cited by 94
Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies
Polvi, E. J., Li, X., O’Meara, T. R., Leach, M. D., & Cowen, L. E. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1860-z · Cited by 104
Restructuring of Enterococcus faecalis biofilm architecture in response to antibiotic-induced stress
Dale, J. L., Nilson, J. L., Barnes, A. M. T., & Dunny, G. M. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0023-4 · Cited by 100
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latgé, J., & Munro, C. A. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch12 · Cited by 107
The Extracellular Matrix of Fungal Biofilms
Mitchell, K. F., Żarnowski, R., & Andes, D. R. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_6 · Cited by 109
Self-citationLobo, C. I. V., Rinaldi, T. B., Christiano, C. M. S., Leite, L. D. S., Barbugli, P. A., & Klein, M. I. (2019) · Journal of Oral Microbiology · doi:10.1080/20002297.2019.1581520 · Cited by 110
Bizerra, F. C., Melo, A. S. D. A., Katchburian, E., Freymüller, E. H., Straus, A. H., Takahashi, H. K., & Colombo, A. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-10 · Cited by 102
Hidden killers: persistence of opportunistic fungal pathogens in the human host
d’Enfert, C. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.05.008 · Cited by 90
Muthamil, S., Balasubramaniam, B., Balamurugan, K., & Pandian, S. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02835 · Cited by 92
“The infection levels are ranging from superficial skin infections to life threatening disseminated infections (d’Enfert et al., 2005; Nett et al., 2007).”
Background
Metadata
- Authors
- Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D.
- Affiliations
- University of Wisconsin–Madison (US)
- Departments of Medicine and Medical Microbiology and Immunology
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-02
- Volume
- 51
- Issue
- 2
- Pages
- 510-520
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC1797745
- OpenAlex
- W1999751604
- Cited by
- 407
- References
- 55
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 19 · 2023: 22 · 2022: 20 · 2021: 15 · 2020: 26 · 2019: 19 · 2018: 22 · 2017: 34 · 2016: 26 · 2015: 28 · 2014: 25 · 2013: 20 · 2012: 23
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T32HL007899)
- National Institute of Allergy and Infectious Diseases (R01AI073289)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- Candida albicans, biofilm, β-1,3-glucan, antifungal resistance, fluconazole resistance, amphotericin B resistance, β-glucanase, cell wall architecture, biofilm matrix, planktonic versus biofilm cells, device-related infection, antifungal susceptibility testing
- MeSH terms
- Amphotericin B, Antifungal Agents, Candida albicans, Microbial Sensitivity Tests, Fluconazole, Biofilms, Drug Resistance, Fungal, Glucan 1,3-beta-Glucosidase, beta-Glucans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.